Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To describe baseline characteristics, effectiveness, persistency, and treatment patterns among first-line b/tsDMARD-naive initiators of etanercept (ETN), adalimumab (ADA), or JAKis (tofacitinib, baricitinib, and upadacitinib).

Next Previous
Trial Profile

To describe baseline characteristics, effectiveness, persistency, and treatment patterns among first-line b/tsDMARD-naive initiators of etanercept (ETN), adalimumab (ADA), or JAKis (tofacitinib, baricitinib, and upadacitinib).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Janus kinase inhibitors
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use

Most Recent Events

  • 15 Nov 2023 Results assessing change in effectiveness and patient-reported outcomes relative to Etanercept initiators; at 6M and 12M follow-up presented at the ACR Convergence 2023
  • 14 Nov 2022 Results assessing the first-line use of etanercept (ETN), adalimumab (ADA), and Janus kinase inhibitors (JAKis) as monotherapies presented at the ACR Convergence 2022.
  • 14 Nov 2022 Results assessing the effectiveness and treatment patterns for patients who had prior treatment with adalimumab (ADA), a tumor necrosis factor inhibitor (TNFi), and switched to either etanercept (ETN) or a Janus kinase inhibitor (JAKi) presented at the ACR Convergence 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top